NCT04455503View on ClinicalTrials.gov

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

March 28, 2023

Conditions
Melanoma Stage IVMelanoma Stage III
Interventions
DRUG

EVX-02A

Up to 8 patients will receive EVX-02A administered IM.

DRUG

EVX-02B

Up to 8 patients will receive EVX-02B administered IM.

DRUG

EVX-02A OR EVX-02B

EVX-02A or EVX-02B will be used. Patients: 24 to 30

Trial Locations (6)

2170

Liverpool Hospital, Goulburn

3000

Peter Maccallum Cancer Centre, Melbourne

3168

Monash Medical Centre, Clayton

3350

Ballarat Health Services, Drummond

5042

Flinders Medical Centre, Adelaide

6009

Linear Cancer Trials, Nedlands

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Evaxion Biotech A/S

INDUSTRY

NCT04455503 - Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | Biotech Hunter | Biotech Hunter